Population genomics in a disease targeted primary cell model.
نویسندگان
چکیده
The common genetic variants associated with complex traits typically lie in noncoding DNA and may alter gene regulation in a cell type-specific manner. Consequently, the choice of tissue or cell model in the dissection of disease associations is important. We carried out an expression quantitative trait loci (eQTL) study of primary human osteoblasts (HOb) derived from 95 unrelated donors of Swedish origin, each represented by two independently derived primary lines to provide biological replication. We combined our data with publicly available information from a genome-wide association study (GWAS) of bone mineral density (BMD). The top 2000 BMD-associated SNPs (P < approximately 10(-3)) were tested for cis-association of gene expression in HObs and in lymphoblastoid cell lines (LCLs) using publicly available data and showed that HObs have a significantly greater enrichment (threefold) of converging cis-eQTLs as compared to LCLs. The top 10 BMD loci with SNPs showing strong cis-effects on gene expression in HObs (P = 6 x 10(-10) - 7 x 10(-16)) were selected for further validation using a staged design in two cohorts of Caucasian male subjects. All 10 variants were tested in the Swedish MrOS Cohort (n = 3014), providing evidence for two novel BMD loci (SRR and MSH3). These variants were then tested in the Rotterdam Study (n = 2090), yielding converging evidence for BMD association at the 17p13.3 SRR locus (P(combined) = 5.6 x 10(-5)). The cis-regulatory effect was further fine-mapped to the proximal promoter of the SRR gene (rs3744270, r(2) = 0.5, P = 2.6 x 10(-15)). Our results suggest that primary cells relevant to disease phenotypes complement traditional approaches for prioritization and validation of GWAS hits for follow-up studies.
منابع مشابه
p38 MAPK and PI3K/AKT signalling cascades in Parkinson’s disease
Parkinson's disease (PD) is a chronic neurodegenerative condition which has the second largest incidence rate among all other neurodegenerative disorders barring Alzheimer's disease (AD). Currently there is no cure and researchers continue to probe the therapeutic prospect in cell cultures and animal models of PD. Out of several factors contributing to PD prognosis, the role of p38 MAPKs (mitog...
متن کاملPleural effusion in lung cancer: more questions than answers.
Lung cancer remains the most common fatal malignancy, despite more aggressive therapies. Few patients will survive 5 years, as up to 80% of the patients will present with advanced-stage disease at diagnosis. Chemotherapy offers little benefit in terms of median survival and disease-free survival in patients with advanced-stage non-small-cell lung carcinoma (NSCLC). In the last decade, the devel...
متن کاملDesign of the optimal magnetic field in application of functionalized CNT-based drug delivery toward the cell membrane: Computational Analysis
Recently, Carbon Nano (CN) structures are widely used in medical applications, especially the detection and treatment of cancer disease. Among various types of CNs, Carbone Nano Tubes (CNTs) attracted many researchers' attention to consider them toward clinical application. Regarding the intrinsic structure of CNTs, they can be used widely in drug delivery applications. Functionalized CNTs and ...
متن کاملI-55: Molecular Imaging Overview
Molecular imaging is the noninvasive visualization of normal as well as abnormal cellular processes at a molecular or genetic level of function. It is used to provide characterization and measurement of biological processes in living animals and humans (in vivo). The discipline of molecular imaging evolved rapidly over the past decade through the integration of cell biology, molecular biology a...
متن کاملWhat Does “Precision Medicine” Have to Say About Prevention?
The Precision Medicine Initiative announced by President Obama aims to be a novel approach to disease treatment and prevention by allowing for individual variability in genes, environment, and lifestyle. Although its immediate goal is to support clinical trials of targeted cancer therapies based on a tumor’s molecular signature, about half of its $200+ million budget for this year is aimed at a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Genome research
دوره 19 11 شماره
صفحات -
تاریخ انتشار 2009